Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
This study will compare two treatment approaches for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor maintenance therapy..One group of participants will receive a combination of the medications sacituzumab govitecan (Trodelvy) and bevacizumab (Avastin)...
Researchers want to know if a computer program can help choose FDA-approved drugs that will treat advanced breast cancer more effectively.
Phase 2 study comparing talazoparib with or without Enzalutamide in patients with metastatic castration-resistant prostate cancer and an HRR mutation after progression on Abiraterone Acetate or Darolutamide
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Update : FDA approves Truqap for some people with metastatic prostate cancer
The Food and Drug Administration (FDA) approved Truqap (capivasertib) with abiraterone and prednisone for adults with metastatic prostate cancer that still responds to hormone-lowering treatment but is missing a protein called PTEN. This approval provides...
Study : Family communication and genetic testing after an inherited cancer risk is identified
A new study found that most people with an inherited cancer-related gene mutation share their results with family members. However, many relatives never pursue genetic testing. This means some relatives may miss opportunities to learn...
Study : Some people with recurrent ovarian cancer have long-lasting benefit from PARP inhibitors
PARP inhibitors are medicines used for some people with ovarian cancer as maintenance therapy after treatment. A new study looked at people whose cancer did not worsen for at least 5 years after starting a...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.